Investor Relations :: SCYNEXIS, Inc. (SCYX)

Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

First Name

Last Name

Email Address

Contact Type:

Sign me up for:

Press Releases

Annual & Quarterly Reports

Current Reports

Insider Transactions

Proxy Information

All Filings

SCYNEXIS to Present Pooled Data Analysis Results Demonstrating Consistent Efficacy and Safety Outcomes Across Two Phase 3 VANISH Clinical Trials of Oral Ibrexafungerp Therapy for Vaginal Yeast Infection at October Medical Conferences

Oct 13, 2021

View All News

Q2 2021

Quarter Ended Jun 30, 2021

PDF HTML

Earnings Release

PDF HTML

10-Q

ZIP XLS HTML

XBRL

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.

Investor Presentation

Download

Symbol

Nasdaq: SCYX

Price

Change

Daily Volume

52-week Low/High

Day Low/High

Investor Contact Information